Antibody–drug conjugates (ADC special)—part 1
Approximation to the magic bullet
- 01.05.2024
- editorial
Erschienen in:
- Verfasst von
-
apl. Prof. Dr. Simon Peter Gampenrieder
Korrespondierender Autor apl. Prof. Dr. Simon Peter Gampenrieder
- University Clinic for Internal Medicine III with hematology, internal oncology, hemostaseology, infectiology, rheumatology and oncology center, University Hospital of the Paracelsus Medical University Salzburg, 5020, Salzburg, Austria
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 2/2024
Auszug
The third generation of antibody–drug conjugates (ADCs) constitute a real breakthrough with a rapid expansion of this innovative treatment approach in different tumor types, making ADCs one of the fastest-growing classes of drugs in oncology. Because ADCs combine the targeting capacity of monoclonal antibodies and the high efficacy of chemotherapeutic payloads, they are not only very effective anticancer treatments, but also less toxic than systemically administered chemotherapeutics. Currently, a total of 15 different ADCs are US Food and Drug Administration (FDA)-approved for different indications, mainly in the metastatic setting. …
Anzeige
- Titel
-
Antibody–drug conjugates (ADC special)—part 1
Approximation to the magic bullet - Verfasst von
-
apl. Prof. Dr. Simon Peter Gampenrieder
- Publikationsdatum
- 01.05.2024
- Verlag
- Springer Vienna
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 2/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-024-00974-w
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.